[Shanghai, October 11, 2025] -- Bivision is pleased to announce a major breakthrough in the field of nuclear medicine, as the core technology supporting its PSMA-targeted radiopharmaceutical was recently formally recognized and granted a patent by the United States Patent and Trademark Office (USPTO) (USPTO) (Patent No.: US12427211B2).

A Bivision R&D leader stated: "We are thrilled to receive this important US patent grant. This is not only an affirmation of our R&D team's relentless efforts but also further strengthens our confidence in advancing innovative radiopharmaceuticals into the global market. We will continue to accelerate the clinical development of JH02, committed to providing more effective diagnostic and therapeutic solutions for prostate cancer patients worldwide."

This significant patent grant marks international recognition by an authoritative body of Bivision's technical capabilities and intellectual property portfolio in the field of innovative radiopharmaceutical R&D. The patent covers the core technology of the company's investigational PSMA-targeted radiopharmaceutical, JH02, providing solid legal protection for the future development, production, and commercialization of this product in the US and global markets.

PSMA is a protein highly expressed on the surface of prostate cancer cells, especially in castration-resistant prostate cancer (CRPC). PSMA-targeted radiopharmaceuticals can precisely deliver radionuclides to cancer cells, enabling accurate tumor diagnosis and treatment, and are expected to bring new treatment options for patients with advanced prostate cancer.